GABA Receptor Agonists - Pipeline Insight, 2022

January 2022 | 90 pages | ID: GA041D90D61EN
DelveInsight

Abstracts

This report can be delivered to the clients within 2-3 working days

DelveInsight’s, “GABA Receptor Agonists - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in GABA Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

GABA Receptor Agonists Understanding

GABA Receptor Agonists: Overview

GABA (?-aminobutyric acid) receptors, of which there are two types, are involved in inhibitory synapses within the central nervous system. The GABAA receptor (GABAAR) has a central role in modern anesthesia and sedation practice, which is evident from the high proportion of agents that target the GABAAR. Many GABAAR agonists are used in anesthesia practice and sedation, including propofol, etomidate, methohexital, thiopental, isoflurane, sevoflurane, and desflurane. There are advantages and disadvantages to each GABAAR agonist currently in clinical use. With increasing knowledge regarding the pharmacology of GABAAR agonists, however, newer sedative agents have been developed which employ ‘soft pharmacology’, a term used to describe the pharmacology of agents whereby their chemical configuration allows rapid metabolism into inactive metabolites after the desired therapeutic effect(s) has occurred. These newer ‘soft’ GABAAR agonists may well approach ideal sedative agents, as they can offer well-controlled, titratable activity and ultrashort action.

'GABA Receptor Agonists - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the GABA Receptor Agonists pipeline landscape is provided which includes the disease overview and GABA Receptor Agonists treatment guidelines. The assessment part of the report embraces, in depth GABA Receptor Agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, GABA Receptor Agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence GABA Receptor Agonists R&D. The therapies under development are focused on novel approaches to treat/improve GABA Receptor Agonists.

GABA Receptor Agonists Emerging Drugs Chapters

This segment of the GABA Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

GABA Receptor Agonists Emerging Drugs

• Ganaxolone: Marinus Pharmaceuticals

Ganaxolone, a positive allosteric modulator of GABAA receptors, is an investigational product being developed in intravenous and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. In August 2021, Marinus Pharmaceuticals announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy.

• EMB-001: Embera NeuroTherapeutics

EMB-001 is a patented combination product comprised of two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiological responses to stress in addiction. It is being developed by Embera NeuroTherapeutics and is currently in Phase II/III stage of development for the treatment of Smoking Cessation and Tobacco Use Disorder.

Further product details are provided in the report……..

GABA Receptor Agonists: Therapeutic Assessment

This segment of the report provides insights about the different GABA Receptor Agonists drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in GABA Receptor Agonists

There are approx. 25+ key companies which are developing the therapies for GABA Receptor Agonists. The companies which have their GABA Receptor Agonists drug candidates in the most advanced stage, i.e. Pre-registration include, Marinus Pharmaceuticals.

• Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

GABA Receptor Agonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

GABA Receptor Agonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses GABA Receptor Agonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging GABA Receptor Agonists drugs.

GABA Receptor Agonists Report Insights

• GABA Receptor Agonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

GABA Receptor Agonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing GABA Receptor Agonists drugs?
• How many GABA Receptor Agonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of GABA Receptor Agonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the GABA Receptor Agonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for GABA Receptor Agonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Marinus Pharmaceuticals
• Embera NeuroTherapeutics
• XWPharma
• Xeris Pharmaceuticals
• Haisco Pharmaceutical Group
• Addex Therapeutics

Key Products

• Ganaxolone
• EMB-001
• XW10172
• XP-0863
• HSK-3486
• Research programme: allosteric modulators

Contents

Introduction
Executive Summary
GABA Receptor Agonists: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Pre-registration)
• Comparative Analysis
Ganaxolone: Marinus Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
• Comparative Analysis
EMB-001: Embera NeuroTherapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
XP-0863: Xeris Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
Research programme: allosteric modulators: Addex Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
GABA Receptor Agonists Key Companies
GABA Receptor Agonists Key Products
GABA Receptor Agonists- Unmet Needs
GABA Receptor Agonists- Market Drivers and Barriers
GABA Receptor Agonists- Future Perspectives and Conclusion
GABA Receptor Agonists Analyst Views
GABA Receptor Agonists Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for GABA Receptor Agonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for GABA Receptor Agonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products